[R-(R,R)]-2-[2-[(DICHLOROACETYL)AMINO]-3-HYDROXY-3-(4-NITROPHENYL)PROPOXY]-2-OXOETHYL HEXADECANOATE


Keyword(s):	Human Metabolites
Molecule Category	Free-form

Structure


InChI Key	DRBVMPGXZZTVQQ-SHQCIBLASA-N
Smiles	CCCCCCCCCCCCCCCC(=O)OCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O
InChI	InChI=1S/C29H44Cl2N2O8/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-25(34)41-21-26(35)40-20-24(32-29(37)28(30)31)27(36)22-16-18-23(19-17-22)33(38)39/h16-19,24,27-28,36H,2-15,20-21H2,1H3,(H,32,37)/t24-,27-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C29H44Cl2N2O8
Molecular Weight	618.25
AlogP	7.32
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	23.0
Polar Surface Area	148.56
Heavy Atoms	41.0

Cross References

Resources	Reference
CAS NUMBER	60595-52-0
NORMAN SUSDAT

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

[R-(R*,R*)]-2-[2-[(DICHLOROACETYL)AMINO]-3-HYDROXY-3-(4-NITROPHENYL)PROPOXY]-2-OXOETHYL HEXADECANOATE

Structure

Physicochemical Descriptors

Cross References

[R-(R,R)]-2-[2-[(DICHLOROACETYL)AMINO]-3-HYDROXY-3-(4-NITROPHENYL)PROPOXY]-2-OXOETHYL HEXADECANOATE